INFLUENCE OF SEX AND AGE ON FLUOROURACIL CLEARANCE

被引:214
作者
MILANO, G
ETIENNE, MC
CASSUTOVIGUIER, E
THYSS, A
SANTINI, J
FRENAY, M
RENEE, N
SCHNEIDER, M
DEMARD, F
机构
[1] Centre Antoine-Lacassagne, Nice
[2] Pharm D, Centre Antoine-Lacassagne, 06054 Nice Cedex
关键词
D O I
10.1200/JCO.1992.10.7.1171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Currently, fluorouracil (5-FU) is one of the major drugs used in cancer chemotherapy. Several investigators, including ourselves, have demonstrated a link between abnormalities in 5-FU clearance (Cl) and the risk of developing more or less 5-FU-related toxicities. Age and sex are among the host factors that have been implicated in the pharmacokinetic variability of drugs. Presently, no data are available on the possible influence of sex and age on 5-FU Cl. Patients and Methods; Three hundred eighty patients (mean age, 61.7 years; range, 25 to 91 ; 301 men and 79 women) with squamous cell carcinoma (sre) of the head and neck were treated in our institution between 1987 and 1991. 5-FU Cl was determined for a total of 1,092 chemotherapy cycles. Each cycle consisted of cisplatin and 5-day continuous intravenous infusion 5-FU (daily doses ranging between 365 and 1,224 mg/m2). Rsults: 5-FU Cl values (L/h/m2) showed a wide disper-sion for both men (median, 179; range, 29 to 739) and women (median, 155; range, 56 to 466). 5-FU Cl values were lower significantly for women compared with men (P = .0005). When adjusted for age and dose, the influence of sex on log Cl remained significant (P = .013). There was no evidence that age modified 5-FU Cl when adjusted for sex and dose. Interestingly, for both men and women, the oldest patients (> 70 years) maintained their ability to clear 5-FU with daily doses that ranged from 500 to 1,000 mg/m2. Conclusions: These data indicate that the capacities to clear 5-FU are lower in women compared with men and are not influenced by age. It would be of interest to know whether this sex-related difference in 5-FU Cl may be clinically revelant by considering both toxicity and tumor response to 5-FU treatment. © 1992 by American Society of Clinical Oncology.
引用
收藏
页码:1171 / 1175
页数:5
相关论文
共 29 条
[1]   SEX-RELATED DIFFERENCE IN THE METABOLISM OF ISOSORBIDE DINITRATE FOLLOWING INCUBATION IN HUMAN-BLOOD [J].
BENNETT, BM ;
TWIDDY, DAS ;
MOFFAT, JA ;
ARMSTRONG, PW ;
MARKS, GS .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (24) :3729-3734
[2]   CONTINUOUS 5-DAY REGIONAL CHEMOTHERAPY BY 5-FLUOROURACIL IN COLON-CARCINOMA - PHARMACOKINETIC EVALUATION [J].
BOUBLIL, JL ;
MILANO, G ;
KHATER, R ;
BOURRY, J ;
THYSS, A ;
BRUNETON, JN ;
RENEE, N ;
PHILIP, C ;
NAMER, M .
BRITISH JOURNAL OF CANCER, 1985, 52 (01) :15-20
[3]  
BREIMER DD, 1983, INT J CLIN PHARM RES, V3, P399
[4]  
CHRISTOPHIDIS N, 1979, CLIN CHEM, V25, P83
[6]   FAMILIAL DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE - BIOCHEMICAL BASIS FOR FAMILIAL PYRIMIDINEMIA AND SEVERE 5-FLUOROURACIL-INDUCED TOXICITY [J].
DIASIO, RB ;
BEAVERS, TL ;
CARPENTER, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) :47-51
[7]   CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL [J].
DIASIO, RB ;
HARRIS, BE .
CLINICAL PHARMACOKINETICS, 1989, 16 (04) :215-237
[8]   CONTINUOUS INFUSION HIGH-DOSE LEUCOVORIN WITH 5-FLUOROURACIL AND CISPLATIN FOR UNTREATED STAGE-IV CARCINOMA OF THE HEAD AND NECK [J].
DREYFUSS, AI ;
CLARK, JR ;
WRIGHT, JE ;
NORRIS, CM ;
BUSSE, PM ;
LUCARINI, JW ;
FALLON, BG ;
CASEY, D ;
ANDERSEN, JW ;
KLEIN, R ;
ROSOWSKY, A ;
MILLER, D ;
FREI, E .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (03) :167-172
[9]   HEPATIC DRUG-METABOLISM AND AGING [J].
DURNAS, C ;
LOI, CM ;
CUSACK, BJ .
CLINICAL PHARMACOKINETICS, 1990, 19 (05) :359-389
[10]   CLEARANCE OF CONTINUOUSLY INFUSED 5-FLUOROURACIL IN ADULTS HAVING LUNG OR GASTROINTESTINAL CARCINOMA WITH OR WITHOUT HEPATIC METASTASES [J].
FLOYD, RA ;
HORNBECK, CL ;
BYFIELD, JE ;
GRIFFITHS, JC ;
FRANKEL, SS .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1982, 16 (09) :665-667